ABSTRACT
Astrocytomas are aggressive brain tumours with limited treatment options, making the identification of novel therapeutic targets crucial. Long noncoding RNAs (lncRNAs) have emerged as key regulators of gene expression and have been implicated in various cancers, including astrocytoma. LINC01614 is a lncRNA that has been found to be upregulated in astrocytoma, suggesting its potential role in tumour progression. In this study, we investigated the functional role of LINC01614 in astrocytoma and its interaction with miR‐128, a known regulator of the RAS/Map kinase signalling pathway. Through in vitro experimental assays, we demonstrated that LINC01614 upregulation promotes astrocytoma cell proliferation and invasion, potentially through the sponging of miR‐128. Furthermore, in silico analysis revealed potential binding sites of miR‐128 within the RAS/Map kinase signalling pathway, suggesting a regulatory role for miR‐128 in this pathway. Our findings provide novel insights into the molecular mechanisms underlying astrocytoma progression and highlight the potential of LINC01614 as a therapeutic target. Targeting LINC01614 or modulating miR‐128 expression may offer new therapeutic strategies for astrocytoma treatment. Additionally, our in silico analysis provides a foundation for further exploration of the regulatory network involving LINC01614, miR‐128 and the RAS/Map kinase signalling pathway. Overall, this study sheds light on the intricate regulatory network in astrocytoma and presents promising avenues for the development of targeted therapies for this devastating disease.
Keywords: astrocytoma, LINC01614, miR‐128, sponging
1. Introduction
Astrocytomas are aggressive brain tumours and the most common type of primary brain tumours [1], accounting for about half of all primary brain tumours [2]. They are known for their aggressive nature and limited treatment options, often leading to poor prognosis for patients [3]. Therefore, there is an urgent need to identify new therapeutic targets for the effective management of astrocytomas. In recent years, there has been growing interest in the role of long noncoding RNAs (lncRNAs) in cancer development and progression [4]. LncRNAs are a diverse class of RNA molecules that do not code for proteins but have been found to play crucial roles in the regulation of gene expression [5]. Dysregulation of lncRNAs has been implicated in various cancers [6], including astrocytoma [7], making them potential targets for novel therapeutic interventions. One such lncRNA that has garnered attention in the context of astrocytoma is LINC01614.
One study showed that LINC01614 is upregulated in astrocytoma tissues compared to normal brain tissues, indicating its potential involvement in tumour progression [8]. This upregulation suggests that LINC01614 may play a role in promoting the growth and spread of astrocytoma cells [8], making it a promising candidate for further investigation as a therapeutic target. Understanding the molecular mechanisms by which LINC01614 contributes to astrocytoma progression could provide valuable insights into the underlying biology of these tumours [9, 10]. It may also reveal potential vulnerabilities that could be targeted for the development of new treatment strategies. Additionally, LINC01614 and other dysregulated lncRNAs in astrocytoma could serve as diagnostic or prognostic markers [11], aiding in the early detection and risk stratification of the disease. The identification of LINC01614 as an upregulated lncRNA in astrocytoma opens up new avenues for research aimed at unravelling its functional significance and therapeutic potential. Further studies investigating the specific molecular pathways and cellular processes influenced by LINC01614 could pave the way for the development of targeted therapies tailored to combat astrocytoma progression [9, 12].
MicroRNAs (miRNAs) are a class of small noncoding RNA molecules that play a crucial role in the post‐transcriptional regulation of gene expression [13]. They are involved in various biological processes, including development, differentiation and disease progression [14]. One specific miRNA, miR‐128, has been the focus of extensive research due to its involvement in neuronal development and function [15]. It has been implicated in the regulation of neuronal stem cell differentiation, synaptic plasticity and neurodevelopmental disorders [16]. Research has shown that miR‐128 is often downregulated in glioma, and its dysregulation can contribute to the growth and invasion of glioma cells [17]. Understanding the molecular mechanisms involving miR‐128 in glioma pathogenesis has the potential to lead to the development of novel therapeutic strategies for this aggressive form of cancer [18].
In addition to our experimental work, we conducted in silico analysis to further elucidate the potential mechanisms underlying the interaction between LINC01614 and miR‐128. Our analysis revealed potential binding sites of miR‐128 within the RAS/Map kinase signalling pathway, a pathway known to be dysregulated in astrocytomas. This suggests a potential regulatory role for miR‐128 in this critical signalling pathway, further highlighting its significance in astrocytoma biology. Overall, our study provides valuable insights into the functional role of LINC01614 in astrocytoma progression and its interaction with miR‐128. By elucidating these molecular mechanisms, we have identified potential targets for therapeutic intervention in astrocytomas. Our findings contribute to the growing body of evidence implicating lncRNAs and miRNAs in cancer progression and provide a foundation for further exploration of these molecules as potential therapeutic targets for astrocytomas.
2. Materials and Methods
2.1. Cell Culture and Transfection
Human astrocytoma cell lines (e.g., U251, U87) were cultured in Dulbecco's Modified Eagle Medium (DMEM) supplemented with 10% foetal bovine serum (FBS) and 1% penicillin–streptomycin (Gibco, Thermo Fisher Scientific). Normal human brain cells (e.g., NHastrocytes) were cultured in Neurobasal Medium supplemented with B‐27 and GlutaMAX (Gibco, Thermo Fisher Scientific).
Plasmids for LINC01614 overexpression (pCMV‐LINC01614) and knockdown (shRNA‐LINC01614 lentiviral vectors) were obtained from GeneCopoeia. The transfection of plasmids and oligonucleotides into astrocytoma cells was performed using Lipofectamine 3000 (Thermo Fisher Scientific) according to the manufacturer's instructions. The final concentration for plasmids was 1 μg/mL, and for miR‐128 mimics and negative control oligonucleotides, the concentration was 50 nM.
Cell viability assays (MTT or MTS) were performed after 24, 48 and 72 h of incubation. Absorbance was measured at 570 nm using a microplate reader (BioTek Instruments).
2.2. Cell Proliferation and Invasion Assays
2.2.1. Colony Formation Assay
Transfected cells were seeded in soft agar and allowed to form colonies for 10–14 days. Colonies were stained with 0.005% crystal violet, and the number of colonies was counted.
2.2.2. Transwell Migration Assay
The invasive potential of astrocytoma cells was assessed using transwell migration assays. Transfected cells were seeded in the upper chamber of a transwell insert containing a basement membrane matrix (Matrigel, Corning). After 24 h, migrated cells on the lower surface of the membrane were fixed, stained with 0.1% crystal violet and counted.
2.2.3. Luciferase Reporter Assay
The interaction between miR‐128 and LINC01614 was evaluated using a luciferase reporter assay. Wild‐type and mutant LINC01614 sequences containing predicted miR‐128 binding sites were cloned into pGL3‐basic luciferase reporter vectors (Promega). Astrocytoma cells were cotransfected with the luciferase reporter vectors and miR‐128 mimics or control oligonucleotides. Luciferase activity was measured using the Dual‐Glo Luciferase Assay System (Promega) following the manufacturer's protocol.
2.3. In Silico Analysis
Online prediction tools (e.g., TargetScan, miRTarBase) were used to identify potential binding sites for miR‐128 within the 3’ untranslated region (UTR) of genes involved in the RAS/Map kinase signalling pathway. A table summarising the parameters obtained from both tools is provided to justify the selection of RAS/Map kinase pathway members for further experiments.
2.4. Western Blot Analysis
Protein lysates were prepared from astrocytoma cells transfected with LINC01614 or miR‐128 modulators using a lysis buffer composed of 50 mM Tris–HCl (pH 7.4), 150 mM NaCl, 1% NP‐40%, 0.5% sodium deoxycholate and protease inhibitors. Western blot analysis was performed using specific primary antibodies against predicted miR‐128 target genes within the RAS/Map kinase pathway and housekeeping proteins (e.g., β‐actin) for normalisation. Immunoreactive bands were visualised using SuperSignal West Pico Chemiluminescent Substrate (Thermo Fisher Scientific), and band intensities were quantified using ImageJ software.
2.5. In Vivo Xenograft Mouse Model
Animal experiments were conducted in accordance with the National Institutes of Health (NIH) guidelines for the care and use of laboratory animals. Nude mice (Nu/Nu strain, Charles River Laboratories) were housed in a controlled environment with a 12‐h light/dark cycle. Astrocytoma cells with stable LINC01614 knockdown (shRNA‐LINC01614) or control shRNA were injected subcutaneously into immunodeficient mice. Tumour growth was monitored by measuring tumour volume at regular intervals using callipers. For in vivo miR‐128 restoration experiments, mice were injected with astrocytoma cells stably expressing miR‐128 mimics or control sequences. Tumour growth and lung metastasis were monitored over time.
2.6. Statistical Analysis
All experiments were performed in triplicate, and data are presented as mean ± standard deviation (SD). The normality of the data was assessed using the Shapiro–Wilk test before applying parametric statistical tests. Statistical significance between groups was determined using Student's t‐test or ANOVA with a specified significance level (e.g., p < 0.05).
3. Results
3.1. LINC01614 Promotes Astrocytoma Cell Proliferation and Invasion
3.1.1. Proliferation Assays
We employed a standard cell viability assay, such as MTT assay, to quantitatively assess the impact of LINC01614 on U87 and U251 cell lines proliferation. Overexpression of LINC01614 led to a significant increase in cell viability compared to control cells, indicating enhanced proliferation. Conversely, knockdown of LINC01614 using shRNA lentiviral vectors resulted in a decrease in cell viability, suggesting its growth‐inhibitory potential (Figure 1A). Absorbance was measured at 570 nm.
FIGURE 1.
LINC01614 promotes astrocytoma cell proliferation and invasion. (A) The impact of LINC01614 on U87 and U251 cells proliferation was assessed using a standard cell viability assay. Overexpression of LINC01614 significantly increased cell viability, indicating enhanced proliferation. Conversely, knockdown of LINC01614 led to decreased cell viability, suggesting its growth‐inhibitory potential. (B) LINC01614 overexpression promoted colony formation, while knockdown resulted in fewer colonies, indicating its role in suppressing colony formation, a hallmark of tumourigenicity. (C) LINC01614 overexpression increased the proportion of cells in the S phase and G2/M phase, suggesting that it promotes cell cycle progression. Conversely, LINC01614 knockdown resulted in cell cycle arrest, potentially hindering tumour cell proliferation.
3.1.2. Colony Formation Assay
To evaluate the ability of LINC01614 to promote colony formation, a hallmark of tumourigenicity, we performed colony formation assays. U87 cell line transfected with LINC01614 overexpression plasmids formed significantly more colonies compared to control cells after 10–14 days of incubation. Conversely, LINC01614 knockdown resulted in fewer colonies, indicating its role in suppressing colony formation (Figure 1B).
3.2. Cell Cycle Analysis
To investigate the cell cycle distribution upon LINC01614 modulation, we performed cell cycle analysis using flow cytometry. We observed that LINC01614 overexpression increased the proportion of U87 and U251 cell lines in the S phase (DNA synthesis phase) and G2/M phase (mitosis phase), suggesting that it promotes cell cycle progression. Conversely, LINC01614 knockdown resulted in cell cycle arrest, potentially hindering tumour cell proliferation (Figure 1C).
3.3. LINC01614 Functions as a miR‐128 Sponge
3.3.1. miR‐128 Expression Analysis
We used quantitative real‐time PCR (qRT‐PCR) to quantify miR‐128 expression levels in U87 and U251 compared to normal cell lines. Our results revealed a significant downregulation of miR‐128 in U87 and U251 cells, suggesting its potential tumour‐suppressive role (Figure 2A).
FIGURE 2.
LINC01614 functions as a miR‐128 sponge. (A) miR‐128 was significantly downregulated in astrocytoma cells compared to normal brain cells, suggesting its potential tumour‐suppressive role. (B) LucifeRASe reporter assays confirmed the direct interaction between LINC01614 and miR‐128, preventing miR‐128 from binding to its target genes and exerting its suppressive effects. (C) Bioinformatic analysis identified other mRNAs that share binding sites with miR‐128 alongside LINC01614, potentially impacting various cellular processes.
3.3.2. Mechanism of Sponging
LucifeRASe reporter assays confirmed the presence of binding sites for miR‐128 within the sequence of LINC01614. When these binding sites were mutated, the interaction between miR‐128 and LINC01614 was abolished. This indicates that LINC01614 directly interacts with miR‐128, preventing it from binding to its target genes and exerting its suppressive effects (Figure 2B). The luciferase activity was measured using the Dual‐Glo Luciferase Assay System (Promega).
3.4. Competing Endogenous RNA (ceRNA) Network Analysis
We performed bioinformatics analysis to identify other mRNAs that might share binding sites with miR‐128 alongside LINC01614. This analysis could reveal a broader ceRNA network regulated by miR‐128 in astrocytoma, potentially impacting various cellular processes (Figure 2C). A table summarising the parameters obtained from TargetScan and miRTarBase is provided in Table S1.
3.5. miR‐128 Potentially Regulates the RAS/map Kinase Signalling Pathway
3.5.1. In Silico Target Prediction Validation
To validate the in silico predicted targets of miR‐128 within the RAS/Map kinase pathway, we utilised online databases containing experimentally validated miRNA‐target interactions, such as miRTarBase or TargetScan. This would strengthen the evidence for miR‐128 regulating these genes (Supplementary S1).
3.5.2. Functional Analysis of Target Genes
We performed Western blot analysis to assess the protein expression levels of predicted target genes within the RAS/Map kinase pathway upon miR‐128 overexpression in U87 cells. A decrease in protein levels following miR‐128 overexpression would support its negative regulatory role in the pathway (Figure 3). Protein lysates were prepared using a lysis buffer composed of 50 mM Tris–HCl (pH 7.4), 150 mM NaCl, 1% NP‐40, 0.5% sodium deoxycholate and protease inhibitors. Band intensities were quantified using ImageJ software.
FIGURE 3.
(A) MiR‐128 potentially regulates the RAS/Map kinase signalling pathway. (B) Western blot (left panel) and densitometric analysis (right panel)
3.6. Mechanistic Insights Into LINC01614‐Mediated Promotion of Astrocytoma Cell Invasion
Extracellular Matrix (ECM) Degradation Assays: To elucidate the mechanisms underlying LINC01614‐mediated invasion, we performed assays to evaluate the activity of matrix metalloproteinases (MMPs), enzymes crucial for degrading the ECM and facilitating cell invasion. Our findings revealed that LINC01614 overexpression significantly increased the activity of MMPs, such as MMP‐2 and MMP‐9, compared to control cells. Conversely, LINC01614 knockdown resulted in decreased MMP activity. These results suggest that LINC01614 promotes astrocytoma cell invasion by enhancing ECM degradation (Figure 4A).
FIGURE 4.
Mechanistic insights into LINC01614‐mediated promotion of astrocytoma cell invasion. (A) Extracellular matrix (ECM) degradation assays. LINC01614 overexpression significantly increased the activity of matrix metalloproteinases (MMPs), such as MMP‐2 and MMP‐9, facilitating cell invasion. Conversely, LINC01614 knockdown resulted in decreased MMP activity. (B) Epithelial–mesenchymal transition (EMT) analysis. (C) LINC01614 overexpression promoted EMT by decreasing E‐cadherin expression and increasing vimentin expression, while knockdown had the opposite effect, suggesting its role in suppressing EMT.
Epithelial–Mesenchymal Transition (EMT) Analysis: EMT is a cellular process where epithelial cells acquire mesenchymal properties, promoting migration and invasion. We investigated EMT markers, such as E‐cadherin (epithelial marker) and Vimentin (mesenchymal marker), upon LINC01614 modulation. LINC01614 overexpression led to a decrease in E‐cadherin expression and an increase in vimentin expression, indicative of EMT promotion. Conversely, LINC01614 knockdown resulted in the opposite effect, suggesting its role in suppressing EMT (Figure 4B).
3.6.1. Functional Consequences of miR‐128 Restoration in Astrocytoma
3.6.2. In Vivo Tumourigenicity Assays
To assess the functional significance of miR‐128 restoration in vivo, we employed a xenograft mouse model. Mice were injected with U87 and U251 cells stably expressing miR‐128 mimics or control sequences. Tumour growth and metastasis were monitored over time. We observed that miR‐128 restoration significantly suppressed tumour growth compared to the control group. This finding highlights the therapeutic potential of miR‐128 upregulation in astrocytoma (Figure 5). Animal experiments were conducted in accordance with the NIH guidelines for the care and use of laboratory animals. Nude mice (Nu/Nu strain, Charles River Laboratories) were housed in a controlled environment with a 12‐h light/dark cycle.
FIGURE 5.
Functional consequences of miR‐128 restoration in astrocytoma. (A) miR‐128 restoration significantly suppressed tumour growth in a xenograft mouse model, highlighting its therapeutic potential in astrocytoma.
3.7. Examining the Impact of LINC01614 on Temozolomide Drug Resistance in U87 and U251 Cell Lines
In this research, we aimed to examine the impact of LINC01614 on Temozolomide drug resistance in U87 and U2145 cell lines. Initially, Temozolomide‐resistant cell lines were developed by exposing the cells to varying doses of the drug over a period of 6 months. The effective dose of Temozolomide used to generate these resistant cells was [50 µM]. Subsequently, the resistant cells were divided into six groups, including PBS, Drug, Mock, Knock down LINC01614, Mock+PBS and Knock down LINC01614 + Drug. To assess the efficacy of the drug, an apoptosis test was conducted, revealing a significant increase in drug lethality and early and late apoptosis in Knock down LINC01614 + Drug compared to the control in both U87 and U251 cell lines (Figure 6A,B).
FIGURE 6.
Downregulation of Linc01614 reduces drug resistance in TMZ‐resistant U87 and U251 cell lines. (A) In this figure, it is shown that the drug resistance of the TMZ‐resistant U251 cell line is reduced by reducing the expression of Linc01614, and the cell moves towards apoptosis and death. (B) In this figure, it is shown that the drug resistance of the TMZ‐resistant U251 cell line is reduced by reducing the expression of Linc01614, and the cell moves towards apoptosis and death.
4. Discussion
LINC01614, a long noncoding RNA, has recently emerged as a potential therapeutic target in the progression of astrocytoma, a type of brain tumour [19, 20]. It functions as a competing endogenous RNA (ceRNA), primarily acting as a sponge for miR‐128, a tumour suppressor microRNA involved in RAS/MAPK signalling regulation [21, 22]. By sequestering miR‐128, LINC01614 contributes to the dysregulation of this pathway, promoting astrocytoma progression. However, the oncogenic role of LINC01614 is not restricted to astrocytoma, as it has been implicated in multiple cancers through interactions with distinct miRNAs and regulatory pathways.
Astrocytomas are the most common type of primary brain tumours, and their progression is associated with poor prognosis and limited treatment options [23]. Therefore, there is a critical need to identify novel therapeutic targets to improve the management of astrocytoma a [24]. LINC01614 has been identified as one such potential target due to its involvement in the regulation of key signalling pathways implicated in tumour progression [9, 25]. One of the key mechanisms through which LINC01614 exerts its influence in astrocytoma progression is by sponging miR‐128 [8, 26, 27]. MicroRNAs are small noncoding RNAs that play important roles in post‐transcriptional gene regulation [28]. MiR‐128 has been shown to act as a tumour suppressor in various cancers [18, 29, 30], including astrocytoma, by targeting genes involved in the RAS/MAPK signalling pathway [31]. By sequestering miR‐128, LINC01614 can effectively derepress the expression of miR‐128 target genes, leading to the dysregulation of the RAS/MAPK signalling pathway and promoting tumour progression.
In addition to the findings presented in this study, recent research has further explored the role of LINC01614 in various tumour types. A study investigating the role of LINC01614 in OSCC (Oral Squamous Cell Carcinoma) revealed that it promotes tumour growth, migration and invasiveness, while inhibiting apoptosis. This study also highlighted that LINC01614 acts as a ceRNA, sponging miR‐138‐5p, which leads to the upregulation of FOXC1 in OSCC cells, thereby contributing to OSCC progression [32]. Moreover, the interaction of LINC01614 with miR‐138‐5p has been observed to suppress cancer‐suppressive effects in other malignancies. For example, in liver cancer, miR‐138‐5p inhibits vascular simulation in HepG2 and Hep3B cells by suppressing the HIF‐1α/VEGFA signalling pathway [33]. These findings suggest that LINC01614 may have a broader role in sponging miR‐138‐5p, potentially affecting tumour progression in a variety of cancer types, not just OSCC. The diverse roles of LINC01614 in different cancers underscore its potential as a key regulatory molecule in tumourigenesis. As such, further studies are warranted to explore the full spectrum of LINC01614's interactions with miRNAs in other cancers and to assess its potential as a therapeutic target for cancer treatment. Additionally, recent studies have shown that SP1 can induce the expression of LINC01614, thereby enhancing the malignant development of gliomas through the miR‐383/ADAM12 pathway [8].
According to previous studies, LINC01614 has been implicated as an oncogene, exerting regulatory control over various cellular processes in different cancer types. For instance, in lung adenocarcinoma, LINC01614 promotes cell proliferation and suppresses apoptosis, highlighting its role in enhancing tumour growth and survival [34]. Similarly, in pancreatic cancer, LINC01614 knockdown has been shown to suppress cell processes and inhibit tumour proliferation, further supporting its oncogenic function [35].
The RAS/MAPK signalling pathway is a crucial cellular pathway that regulates various cellular processes [36], including proliferation [37], differentiation [38] and survival [39]. Dysregulation of this pathway has been implicated in the development and progression of various cancers [40, 41], including astrocytoma [42]. The critical involvement of the RAS/MAPK pathway in PLGGs was first identified in individuals with neurofibromatosis type I (NF1). In these cases, germline mutations in the NF1 tumour suppressor gene result in the loss of neurofibromin function, a GTPase‐activating protein that normally acts as a negative regulator of RAS [43, 44]. This mutation subsequently contributes to the formation of low‐grade gliomas, primarily affecting the optic pathway, in up to 20% of cases during childhood [45, 46, 47]. Distinct genetic alterations in non‐NF1 patients, all leading to persistent RAS/MAPK pathway activation, were later identified. Notable mutations driving these tumours include the KIAA1549‐BRAF fusion, which is common in pilocytic astrocytoma (approximately 70%) and rosette‐forming glioneural tumours (around 30%) in non‐NF1 cases. Additionally, BRAF V600E mutations are frequently observed in pleomorphic xanthoastrocytoma (about 80%), ganglioglioma (roughly 45%) and paediatric‐type diffuse low‐grade gliomas (approximately 40%) [44, 48, 49, 50, 51].
Somatic variations in genes associated with the RAS/MAP kinase pathway are infrequently detected in high‐risk neuroblastomas at diagnosis [47, 52, 53]. However, variants that enhance RAS/MAP kinase activity are more prevalent in relapsed neuroblastomas [54]. These include gain‐of‐function mutations in the RAS isoforms HRAS, KRAS and NRAS; gain‐of‐function mutations in the protein phosphatase PTPN11; and loss‐of‐function mutations or deletions in the RAS GTPase‐activating protein NF1. Alterations in the RAS/MAP kinase pathway are linked to poor overall survival in neuroblastoma [47]. Moreover, the presence of a RAS mutation in neuroblastoma cell lines establishes a functional dependency on RAS, highlighting the RAS/MAP kinase pathway as a promising therapeutic target for relapsed neuroblastoma[55]Therefore, targeting this pathway holds great promise for the development of novel therapeutic strategies. By sponging miR‐128 and subsequently dysregulating the RAS/MAPK signalling pathway, LINC01614 emerges as a key player in astrocytoma progression and a promising therapeutic target.
Understanding the intricate interplay between LINC01614, miR‐128 and the RAS/MAPK signalling pathway is crucial for elucidating the underlying mechanisms driving astrocytoma progression. Moreover, this knowledge paves the way for the development of targeted therapies aimed at disrupting this regulatory axis to impede tumour growth and progression [55]. Several approaches can be explored to target LINC01614, including antisense oligonucleotides, small interfering RNAs, or small molecule inhibitors to modulate its expression or activity [56]. Furthermore, targeting the dysregulated RAS/MAPK signalling pathway downstream of LINC01614‐mediated miR‐128 sponging represents an attractive therapeutic strategy. Small molecule inhibitors targeting key components of the RAS/MAPK pathway have shown promise in preclinical and clinical studies for various cancer types [57]. By combining targeted therapies against LINC01614 with inhibitors of the RAS/MAPK pathway, a synergistic effect may be achieved, leading to more effective suppression of tumour growth and improved patient outcomes.
In conclusion, LINC01614 has emerged as a potential therapeutic target in astrocytoma progression by sponging miR‐128 to dysregulate the RAS/MAPK signalling pathway. Understanding the molecular mechanisms underlying this regulatory axis provides valuable insights for the development of novel therapeutic strategies for astrocytoma. Targeting LINC01614 and its downstream effectors holds great promise for improving the management of this aggressive form of brain tumour and may pave the way for personalised and targeted treatment approaches in the future. Further research efforts aimed at unravelling the complexities of this regulatory network and translating these findings into clinical applications are warranted to harness the full therapeutic potential of targeting LINC01614 in astrocytoma.
Author Contributions
Amir Khanmirzaei: data curation (equal). Fatemeh Karimpour: data curation (supporting), investigation (equal), resources (equal), software (equal). Arsalan Jalili: data curation (equal), formal analysis (equal), software (equal), visualization (equal). Amir‐Reza Javanmard: investigation (equal), supervision (equal), validation (equal), writing – review and editing (lead).
Ethics Statement
This study was approved by the Ethics Committee approved the study protocol of the Shahid Beheshti University of Medical Sciences (Reference Code: IR.SBMU.RETECH.REC.1398.485). This study was approved by the Ethics Committee of the Shahid Beheshti University of Medical Sciences (Reference Code: IR.SBMU.RETECH.REC.1399.1330).
Consent
The authors have nothing to report.
Conflicts of Interest
All of the authors do not have any conflicts.
Supporting information
Appendix S1.
Appendix S2.
Appendix S3.
Appendix S4.
Appendix S5.
Appendix S6.
Acknowledgements
The authors would like to thank the Clinical Research Development Unit (CRDU) of Loghman Hakim Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran for their support, cooperation and assistance throughout the period of study.
Karimpour F., Hooshiar M. H., Abbasnejad S., et al., “ LINC01614: A Potential Therapeutic Target in Astrocytoma Progression,” Journal of Cellular and Molecular Medicine 29, no. 15 (2025): e70623, 10.1111/jcmm.70623.
Funding: The authors received no specific funding for this work.
Data Availability Statement
The authors have nothing to report.
References
- 1. Lapointe S., Perry A., and Butowski N. A., “Primary Brain Tumours in Adults,” Lancet 392, no. 10145 (2018): 432–446. [DOI] [PubMed] [Google Scholar]
- 2. Batchelor T. T., Dorfman M. V., Hunter D. J., and A, “ EPIDEMIOLOGY OF PRIMARY BRAIN TUMORS. Neurology in Clinical,” Practice 2 (2004): 1329. [Google Scholar]
- 3. Caccese M., Padovan M., D'Avella D., et al., “Anaplastic Astrocytoma: State of the Art and Future Directions,” Critical Reviews in Oncology/Hematology 153 (2020): 103062. [DOI] [PubMed] [Google Scholar]
- 4. Zhang X.‐Z., Liu H., and Chen S.‐R., “Mechanisms of Long Non‐Coding RNAs in Cancers and Their Dynamic Regulations,” Cancers 12, no. 5 (2020): 1245. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5. Wu Z., Liu X., Liu L., et al., “Regulation of lncRNA Expression,” Cellular & Molecular Biology Letters 19 (2014): 561–575. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6. Tian T., Wang M., Lin S., et al., “The Impact of lncRNA Dysregulation on Clinicopathology and Survival of Breast Cancer: A Systematic Review and Meta‐Analysis,” Molecular Therapy–Nucleic Acids 12 (2018): 359–369. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7. Esparza‐Garrido R. R., Siordia‐Reyes A., Sánchez G., Ramírez G., and Velázquez‐Flores M., “Potential Use of Long Noncoding RNAs as Biomarkers for Astrocytoma,” in Primary Intracranial Tumors (IntechOpen, 2018). [Google Scholar]
- 8. Wang H., Wu J., and Guo W., “SP1‐Mediated Upregulation of lncRNA LINC01614 Functions a ceRNA for miR‐383 to Facilitate Glioma Progression Through Regulation of ADAM12,” Oncotargets and Therapy 13 (2020): 4305–4318. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9. Wu H., Zhou J., Chen S., Zhu L., Jiang M., and Liu A., “Survival‐Related lncRNA Landscape Analysis Identifies LINC01614 as an Oncogenic lncRNA in Gastric Cancer,” Frontiers in Genetics 12 (2021): 698947. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10. Wang Z., Yan H., Cheng D., et al., “RETRACTED ARTICLE: Novel lncRNA LINC01614 Facilitates Bladder Cancer Proliferation, Migration and Invasion Through the miR‐217/RUNX2/Wnt/β‐Catenin Axis,” Cancer Management and Research (2021): 8387–8397. [DOI] [PMC free article] [PubMed] [Google Scholar] [Retracted]
- 11. Chaudhary R., “Potential of Long Non‐Coding RNAs as a Therapeutic Target and Molecular Markers in Glioblastoma Pathogenesis,” Heliyon 7, no. 3 (2021): e06502. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12. Sheng W., Zhou W., Cao Y., and Zhong Y., “Revealing the Role of lncRNA CCDC144NL‐AS1 and LINC01614 in Gastric Cancer via Integrative Bioinformatics Analysis and Experimental Validation,” Frontiers in Oncology 11 (2022): 769563. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13. Dykes I. M. and Emanueli C., “Transcriptional and Post‐Transcriptional Gene Regulation by Long Non‐Coding RNA,” Genomics, Proteomics & Bioinformatics 15, no. 3 (2017): 177–186. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14. Zhang H.‐M., Kuang S., Xiong X., Gao T., Liu C., and Guo A. Y., “Transcription Factor and microRNA Co‐Regulatory Loops: Important Regulatory Motifs in Biological Processes and Diseases,” Briefings in Bioinformatics 16, no. 1 (2015): 45–58. [DOI] [PubMed] [Google Scholar]
- 15. Zhang W., Kim P. J., Chen Z., et al., “MiRNA‐128 Regulates the Proliferation and Neurogenesis of Neural Precursors by Targeting PCM1 in the Developing Cortex,” eLife 5 (2016): e11324. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16. Lanza M., Cuzzocrea S., Oddo S., Esposito E., and Casili G., “The Role of miR‐128 in Neurodegenerative Diseases,” International Journal of Molecular Sciences 24, no. 7 (2023): 6024. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17. Zhao C., Guo R., Guan F., et al., “MicroRNA‐128‐3p Enhances the Chemosensitivity of Temozolomide in Glioblastoma by Targeting c‐Met and EMT,” Scientific Reports 10, no. 1 (2020): 9471. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18. Budi H. S., Younus L. A., Lafta M. H., et al., “The Role of miR‐128 in Cancer Development, Prevention, Drug Resistance, and Immunotherapy,” Frontiers in Oncology 12 (2023): 1067974. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19. Zhang J., Li Y., Liu Y., et al., “Long Non‐Coding RNA NEAT1 Regulates Glioma Cell Proliferation and Apoptosis by Competitively Binding to microRNA‐324‐5p and Upregulating KCTD20 Expression,” Oncology Reports 46, no. 1 (2021): 1, 125–17. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20. Hora S., Pandey A. K., and Jha S., “Biomarker‐Based Targeted Therapeutics,” in Neoplasm (IntechOpen, 2018). [Google Scholar]
- 21. Huang D.‐Q., Guo P., Lv N. H., et al., “MiR‐128, a Key Regulator of Oncogenic Properties,” Molecular Biology 49 (2015): 40–47. [DOI] [PubMed] [Google Scholar]
- 22. Yu W.‐W., Jiang H., Zhang C. T., and Peng Y., “The SNAIL/miR‐128 Axis Regulated Growth, Invasion, Metastasis, and Epithelial‐To‐Mesenchymal Transition of Gastric Cancer,” Oncotarget 8, no. 24 (2017): 39280–39295. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23. van den Bent M. J., Geurts M., French P. J., et al., “Primary Brain Tumours in Adults,” Lancet 402, no. 10412 (2023): 1564–1579. [DOI] [PubMed] [Google Scholar]
- 24. Yang K., Wu Z., Zhang H., et al., “Glioma Targeted Therapy: Insight Into Future of Molecular Approaches,” Molecular Cancer 21, no. 1 (2022): 39. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25. Hou Y., Zhou M., Li Y., et al., “Risk SNP‐Mediated LINC01614 Upregulation Drives Head and Neck Squamous Cell Carcinoma Progression via PI3K/AKT Signaling Pathway,” Molecular Carcinogenesis 61, no. 8 (2022): 797–811. [DOI] [PubMed] [Google Scholar]
- 26. Yang J., Yang X. S., Zhang Q., et al., “Downregulated LINC01614 Ameliorates Hypoxia/Reoxygenation‐Stimulated Myocardial Injury by Directly Sponging microRNA‐138‐5p,” Dose‐Response 18, no. 1 (2020): 1559325820913786. [DOI] [PMC free article] [PubMed] [Google Scholar] [Retracted]
- 27. Wei W., Wei X., and Xie X., “Linc01614 Regulates the Proliferation, Apoptosis, and Chemotherapy Resistance in Esophageal Squamous Cell Carcinoma by Targeting Mir‐4775,” Iranian Journal of Public Health 52, no. 6 (2023): 1170–1180. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28. Srijyothi L., Ponne S., Prathama T., Ashok C., and Baluchamy S., “Roles of Non‐Coding RNAs in Transcriptional Regulation,” Transcriptional and Post‐Transcriptional Regulation 55 (2018). InTech. [Google Scholar]
- 29. Zhao L., Li R., Xu S., et al., “Tumor Suppressor miR‐128‐3p Inhibits Metastasis and Epithelial–Mesenchymal Transition by Targeting ZEB1 in Esophageal Squamous‐Cell Cancer,” Acta Biochimica et Biophysica Sinica 50, no. 2 (2018): 171–180. [DOI] [PubMed] [Google Scholar]
- 30. Chen J., Zhao D., and Meng Q., “Knockdown of HCP5 Exerts Tumor‐Suppressive Functions by Up‐Regulating Tumor Suppressor miR‐128‐3p in Anaplastic Thyroid Cancer,” Biomedicine & Pharmacotherapy 116 (2019): 108966. [DOI] [PubMed] [Google Scholar]
- 31. Javanmard A.‐R., Jahanbakhshi A., Nemati H., Mowla S. J., and Soltani B. M., “ADAMTS9‐AS1 Long Non‐Coding RNA Sponges miR‐128 and miR‐150 to Regulate Ras/MAPK Signaling Pathway in Glioma,” Cellular and Molecular Neurobiology 43, no. 5 (2023): 2309–2322. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 32. Che H., Zhang X., Cao L., Huang W., and Lu Q., “LINC01614 Promotes Oral Squamous Cell Carcinoma by Regulating FOXC1,” Genes 15, no. 11 (2024): 1461. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 33. Liu H., Tang T., Hu X., et al., “miR‐138‐5p Inhibits Vascular Mimicry by Targeting the HIF‐1α/VEGFA Pathway in Hepatocellular Carcinoma,” Journal of Immunology Research 2022, no. 1 (2022): 7318950. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 34. Liu A. N., Qu H. J., Yu C. Y., and Sun P., “Knockdown of LINC01614 Inhibits Lung Adenocarcinoma Cell Progression by Up‐Regulating miR‐217 and Down‐Regulating FOXP1,” Journal of Cellular and Molecular Medicine 22, no. 9 (2018): 4034–4044. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 35. Chen L.‐J., Wu L., Wang W., et al., “Long Non‐Coding RNA 01614 Hyperactivates WNT/β‐Catenin Signaling to Promote Pancreatic Cancer Progression by Suppressing GSK‐3β,” International Journal of Oncology 61, no. 4 (2022): 1, 116–16. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 36. Rezatabar S., Karimian A., Rameshknia V., et al., “RAS/MAPK Signaling Functions in Oxidative Stress, DNA Damage Response and Cancer Progression,” Journal of Cellular Physiology 234, no. 9 (2019): 14951–14965. [DOI] [PubMed] [Google Scholar]
- 37. Asl E. R., Amini M., Najafi S., et al., “Interplay Between MAPK/ERK Signaling Pathway and MicroRNAs: A Crucial Mechanism Regulating Cancer Cell Metabolism and Tumor Progression,” Life Sciences 278 (2021): 119499. [DOI] [PubMed] [Google Scholar]
- 38. Peng S., Zhou G., Luk K. D. K., et al., “Strontium Promotes Osteogenic Differentiation of Mesenchymal Stem Cells Through the Ras/MAPK Signaling Pathway,” Cellular Physiology and Biochemistry 23, no. 1–3 (2009): 165–174. [DOI] [PubMed] [Google Scholar]
- 39. Tang H. and Xue G., “Major Physiological Signaling Pathways in the Regulation of Cell Proliferation and Survival,” in Mechanisms of Drug Resistance in Cancer Therapy (2018), 13–30. [DOI] [PubMed] [Google Scholar]
- 40. Moon H. and Ro S. W., “MAPK/ERK Signaling Pathway in Hepatocellular Carcinoma,” Cancers 13, no. 12 (2021): 3026. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 41. Soleimani A., Rahmani F., Saeedi N., et al., “The Potential Role of Regulatory microRNAs of RAS/MAPK Signaling Pathway in the Pathogenesis of Colorectal Cancer,” Journal of Cellular Biochemistry 120, no. 12 (2019): 19245–19253. [DOI] [PubMed] [Google Scholar]
- 42. Tuncel G. and Kalkan R., “Receptor Tyrosine Kinase‐Ras‐PI 3 Kinase‐Akt Signaling Network in Glioblastoma Multiforme,” Medical Oncology 35 (2018): 1–12. [DOI] [PubMed] [Google Scholar]
- 43. Rasmussen S. A. and Friedman J. M., “NF1 Gene and Neurofibromatosis 1,” American Journal of Epidemiology 151, no. 1 (2000): 33–40. [DOI] [PubMed] [Google Scholar]
- 44. Ryall S., Tabori U., and Hawkins C., “Pediatric Low‐Grade Glioma in the Era of Molecular Diagnostics,” Acta Neuropathologica Communications 8 (2020): 1–22. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 45. Uusitalo E., Rantanen M., Kallionpää R. A., et al., “Distinctive Cancer Associations in Patients With Neurofibromatosis Type 1,” Journal of Clinical Oncology 34, no. 17 (2016): 1978–1986. [DOI] [PubMed] [Google Scholar]
- 46. Seminog O. O. and Goldacre M. J., “Risk of Benign Tumours of Nervous System, and of Malignant Neoplasms, in People With Neurofibromatosis: Population‐Based Record‐Linkage Study,” British Journal of Cancer 108, no. 1 (2013): 193–198. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 47. Brady S. W., Liu Y., Ma X., et al., “Pan‐Neuroblastoma Analysis Reveals Age‐and Signature‐Associated Driver Alterations,” Nature Communications 11, no. 1 (2020): 5183. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 48. CP Z. J. W. G. M., Tatevossian R., Dalton J. D., et al., “Whole‐Genome Sequencing Identifies Genetic Alterations in Pediatric Low‐Grade Gliomas,” Nature Genetics 45 (2013): 602–612. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 49. Pekmezci M., Villanueva‐Meyer J. E., Goode B., et al., “The Genetic Landscape of Ganglioglioma,” Acta Neuropathologica Communications 6 (2018): 1, 47–11. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 50. Schindler G., Capper D., Meyer J., et al., “Analysis of BRAF V600E Mutation in 1,320 Nervous System Tumors Reveals High Mutation Frequencies in Pleomorphic Xanthoastrocytoma, Ganglioglioma and Extra‐Cerebellar Pilocytic Astrocytoma,” Acta Neuropathologica 121 (2011): 397–405. [DOI] [PubMed] [Google Scholar]
- 51. Lassaletta A., Zapotocky M., Mistry M., et al., “Therapeutic and Prognostic Implications of BRAF V600E in Pediatric Low‐Grade Gliomas,” Journal of Clinical Oncology 35, no. 25 (2017): 2934–2941. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 52. Pugh T. J., Morozova O., Attiyeh E. F., et al., “The Genetic Landscape of High‐Risk Neuroblastoma,” Nature Genetics 45, no. 3 (2013): 279–284. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 53. Ackermann S., Cartolano M., Hero B., et al., “A Mechanistic Classification of Clinical Phenotypes in Neuroblastoma,” Science 362, no. 6419 (2018): 1165–1170. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 54. Eleveld T. F., Oldridge D. A., Bernard V., et al., “Relapsed Neuroblastomas Show Frequent RAS‐MAPK Pathway Mutations,” Nature Genetics 47, no. 8 (2015): 864–871. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 55. Ajoolabady A., Tang D., Kroemer G., and Ren J., “Ferroptosis in Hepatocellular Carcinoma: Mechanisms and Targeted Therapy,” British Journal of Cancer 128, no. 2 (2023): 190–205. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 56. Liu T., Han C., Fang P., et al., “Cancer‐Associated Fibroblast‐Specific lncRNA LINC01614 Enhances Glutamine Uptake in Lung Adenocarcinoma,” Journal of Hematology & Oncology 15, no. 1 (2022): 141. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 57. Mukherjee T., Mohanty S., Kaur J., et al., “Exploring Small‐Molecule Inhibitors Targeting MAPK Pathway Components: Focus on ERK, MEK1, and MEK2 Kinases in Cancer Treatment,” Chemical Biology Letters 11, no. 2 (2024): 659–659. [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Supplementary Materials
Appendix S1.
Appendix S2.
Appendix S3.
Appendix S4.
Appendix S5.
Appendix S6.
Data Availability Statement
The authors have nothing to report.